申请人:Hoechst Aktiengesellschaft
公开号:US05559153A1
公开(公告)日:1996-09-24
Urea-substituted benzoylguanidines, process for their preparation, their use as pharmaceutical or diagnostic, and pharmaceutical containing them There are described benzoylguanidines of the formula I ##STR1## where R(1), R(3) or R(4) is --NR(6) C.dbd.X NR(7)R(8); X is oxygen, sulfur, R(6), R(7) and R(8) are H, (perfluoro)alk(en)yl, where R(7) and R(8) can also together be 4 or 5 methylene groups, the substituents R(1) to R(5) remaining in each case are H, Hal, (fluoro) alk(en)yl, CN, NO.sub.2, NR(16)R(17). On account of their pharmacological properties, the compounds are outstandingly suitable for use as anti-arrhythmic pharmaceuticals having a cardioprotective component for the prophylaxis and treatment of infarction as well as for the treatment of angina pectoris, the compounds also inhibiting or strongly reducing, in a preventive manner, the pathophysiological processes in association with the occurrence of ischemically induced damage, in particular in association with the elicitation of ischemically induced cardiac arrhythmias. They are obtained by reacting a compound of the formula II. ##STR2## in which L is a leaving group which can readily be substituted nucleophilically, with guanidine.
尿素取代苯甲酰胍,其制备方法,其用途作为药用或诊断药物,以及含有它们的药物。描述了式I的苯甲酰胍##STR1##其中R(1),R(3)或R(4)为--NR(6) C.dbd.X NR(7)R(8);X为氧,硫,R(6),R(7)和R(8)为H,(全氟)烷基,其中R(7)和R(8)也可以共同为4或5个亚甲基基团,每种情况下保持不变的取代基R(1)到R(5)为H,卤素,(氟)烷基,CN,NO.sub.2,NR(16)R(17)。由于它们的药理特性,这些化合物非常适合用作具有心脏保护成分的抗心律失常药物,用于预防和治疗梗死以及治疗心绞痛,这些化合物还以预防性方式抑制或强烈减少与缺血性损伤发生相关的病理生理过程,特别是与诱发缺血性心律失常相关的病理生理过程。它们是通过将式II的化合物反应而得到的。##STR2##其中L是一个易于被亲核取代的离去基团,与胍反应。